Bod1l is required to suppress deleterious resection of stressed replication forks

Higgs, Martin; Reynolds, John; Winczura, Alicja; Blackford, AN; Borel, Valerie; Miller, Edward; Zlatanou, Anastasia; Nieminuszczy, Jadwiga; Ryan, Ellis; Davies, Nicholas; Stankovic, Tatjana; Boulton, Simon; Niedzwiedz, Wojciech; Stewart, Grant

DOI:
10.1016/j.molcel.2015.06.007

License:
None: All rights reserved

Citation for published version (Harvard):
https://doi.org/10.1016/j.molcel.2015.06.007

Link to publication on Research at Birmingham portal

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

•Users may freely distribute the URL that is used to identify this publication.
•Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
•User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.
BOD1L IS REQUIRED TO SUPPRESS DELETERIOUS RESECTION OF STRESSED REPLICATION FORKS

Martin R. Higgs\textsuperscript{1,4}, John J. Reynolds\textsuperscript{1,4}, Alicja Winczura\textsuperscript{2a}, Andrew N. Blackford\textsuperscript{2b}, Valérie Borel\textsuperscript{3}, Edward S. Miller\textsuperscript{10}, Anastasia Zlatanou\textsuperscript{1}, Jadwiga Nieminuszczy\textsuperscript{2}, Ellis L. Ryan\textsuperscript{1}, Nicholas J. Davies\textsuperscript{1}, Tatjana Stankovic\textsuperscript{1}, Simon J. Boulton\textsuperscript{3}, Wojciech Niedzwiedz\textsuperscript{2}, Grant S. Stewart\textsuperscript{11}.

\textsuperscript{1} School of Cancer Sciences, University of Birmingham, Birmingham, B15 2TT, UK
\textsuperscript{2} The Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK.
\textsuperscript{3} London Research Institute, Clare Hall Laboratories, South Mimms, Herts, EN6 3LD, UK.
\textsuperscript{4} Co-first author.
\textsuperscript{11} Correspondence: g.s.stewart@bham.ac.uk
\textsuperscript{10} Current address: Wellcome Trust/Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge, CB2 1QN, UK.
\textsuperscript{9} Current address: Division of Biomedical Cell Biology, The University of Warwick, Coventry, CV4 7AL, UK.

\textbf{RUNNING TITLE:} BOD1L prevents DNA-2 dependent fork resection

\textbf{CHARACTER COUNT:} 59,966
Recognition and repair of damaged replication forks is essential to maintain genome stability, and is coordinated by the combined action of the Fanconi Anaemia and homologous recombination pathways. These pathways are vital to protect stalled replication forks from uncontrolled nucleolytic activity, which otherwise causes irreparable genomic damage. Here we identify BOD1L as a component of this fork protection pathway, which safeguards genome stability after replication stress. Loss of BOD1L confers exquisite cellular sensitivity to replication stress and uncontrolled resection of damaged replication forks, due to a failure to stabilise Rad51 at these forks. Blocking DNA2-dependent resection, or down regulation of the helicases BLM and Fbh1, suppresses both catastrophic fork processing and the accumulation of chromosomal damage in BOD1L-deficient cells. Thus, our work implicates BOD1L as a critical regulator of genome integrity that restrains nucleolytic degradation of damaged replication forks.
INTRODUCTION

Replication stress is any pathological process that compromises the fidelity of genome duplication (Zeman and Cimprich, 2014). The Fanconi Anaemia (FA)/homologous recombination (HR) pathway plays a central role in combatting replication stress (Gari and Constantinou, 2009). FA is a rare chromosomal instability syndrome characterized by severe developmental abnormalities, tumour predisposition and a hypersensitivity to agents that induce DNA inter-strand cross-links (ICLs), such as mitomycin C (MMC) and cisplatin. To date, mutations in at least 16 different genes (FA complementation groups A-Q) have been identified in patients exhibiting features consistent with FA (reviewed in Walden and Deans, 2014).

Whilst historically the FA/HR pathway has been associated with the HR-dependent repair of ICLs, it plays a broader role in protecting cells from replication stress. Indeed, HR-deficient (and some FA) cell lines are hypersensitive to replication stress-inducing agents that do not induce ICLs (e.g. aphidicolin [APH] and hydroxyurea [HU]) (Howlett et al., 2005). It has been proposed that FA and HR proteins function to: (i) protect stalled/collapsed forks from uncontrolled nucleolytic attack (which may render such forks unrecoverable and/or prone to inappropriate repair) (Schlacher et al., 2011; 2012); and (ii) in some cases may facilitate their restart once repair is complete. Cells defective in these processes exhibit an increase in under-replicated DNA, particularly at common fragile sites (CFS). This can result in the generation of ultra-fine anaphase bridges (UFBs), and can ultimately manifest as chromosome breakage and micronuclei (Naim and Roselli, 2009a). The accumulation of such genetic damage over time eventually triggers cell death, and may contribute to the attrition of highly replicating cells, such as germ and haematopoietic cells (Garaycoechea and Patel, 2014).

Despite extensive research, it is still not completely understood how the cell regulates repair of replication damage via the FA/HR pathway. A wide variety of DNA damage response (DDR) and DNA repair proteins, including components of the FA/HR pathway, are recruited to stalled forks upon replication stress (Sirbu et al., 2013). However, it is unclear how replication forks requiring repair are marked: this might involve RPA coated ssDNA, specific DNA secondary structures or damage-inducible post-translational modifications of the replication machinery and/or...
surrounding chromatin. It is also likely that some repair proteins are constitutive components of the replication fork machinery, to allow immediate initiation of the DDR once a lesion is encountered.

We have identified an uncharacterised factor, BOD1L, associated with newly replicated chromatin. Cells lacking BOD1L accumulate catastrophic levels of genome damage following replication stress, particularly after MMC exposure, manifesting as excessive chromosome breakage. Although related to the mitotic regulator BOD1, we demonstrate that BOD1L does not regulate spindle orientation but rather functions to protect stalled/damaged replication forks from uncontrolled DNA2-dependent resection. We further show that BOD1L functions within the FA pathway as part of the fork protection machinery, to stabilize Rad51 on chromatin by suppressing the anti-recombinogenic and pro-resection activities of Fbh1 and BLM. Taken together, our data establish that BOD1L is a critical factor associated with the replication machinery that acts to promote fork stability by counteracting negative regulators of HR.
RESULTS

**BOD1L is an uncharacterised factor that maintains genome stability following replication stress**

Isolation of proteins on nascent DNA (iPOND) is a robust method for the detection of proteins at sites of newly replicated DNA (Sirbu et al., 2013). However, many proteins are sensitive to the harsh conditions of iPOND. To overcome this issue, we first modified the original iPOND protocol and subsequently utilised this new method coupled with mass spectrometry to identify factors associated with nascent chromatin. As with other iPOND-based proteomic studies (Sirbu et al., 2013), we identified numerous replication machinery components at ongoing forks, including the MCM helicase, PCNA, the RFC complex, RPA and the replicative polymerases, polδ and polα (Figure S1A). In addition to these proteins, we also identified Biorientation Defect 1-like (BOD1L); a large, previously uncharacterised protein with N-terminal homology to the mitotic regulator BOD1 (Figure 1A) (Porter et al., 2007). Consistent with these data, we confirmed the presence of BOD1L in EdU precipitates by Western blotting (Figure 1B). To verify that BOD1L associated with replication fork proteins, we performed proximity-ligation assays with antibodies against PCNA and BOD1L. We readily detected nuclear PLA signals in undamaged EdU-positive cells, which were strongly reduced in EdU-negative and BOD1L-depleted cells (Figures 1C-D). Moreover, we could co-immunoprecipitate BOD1L, and murine GFP-tagged Bod1L, with Mcm2 and Mcm7 (Figures 1E and S1B). Together, these data indicate that BOD1L is localised at/near replication forks.

In addition to its homology to BOD1, the amino acid sequence of BOD1L also contains several *in vivo* ATM/ATR phosphorylation sites (Matsuoka et al. (2007)), suggesting that BOD1L might play a role in the DDR. To investigate this, we depleted cells of BOD1L using siRNA and analysed cellular sensitivity to a range of DNA damaging agents. Knockdown of BOD1L exquisitely hypersensitised cells to agents that induce replicative stress, in particular MMC (Figures 1F and S1C), and was significantly more severe than loss of FANCA. However, co-depletion of FANCA and BOD1L revealed that these two factors were epistatic for MMC hypersensitivity, suggesting that BOD1L may function within the FA pathway. Treatment of BOD1L-depleted cells with replication stress-inducing agents also induced increased micronuclei formation, indicating a critical role for BOD1L in maintaining genome stability upon replication damage (Figure 1G).
Importantly, these observations were recapitulated in several cell lines, and in two independent DT40 BOD1L knockout clones (Figures S1D-H), demonstrating that the genome instability observed is specifically due to loss of BOD1L, and is neither cell line nor organism specific.

**BOD1L and BOD1 are functionally distinct**

BOD1 is a mitotic factor that associates with metaphase chromosomes and is essential for correct orientation of the mitotic spindle (Porter et al., 2007; Porter et al., 2013). Given the sequence similarity of the N-terminus of BOD1L to BOD1, it was conceivable that the increased micronuclei observed in BOD1L-depleted cells arose from mitotic abnormalities.

To first investigate whether BOD1L was functionally related to BOD1, we performed phenotypic analyses of cells depleted of either BOD1 or BOD1L by siRNA. Whilst loss of BOD1L resulted in elevated DDR signalling, specifically the phosphorylation of H2AX and RPA2, this defect was not observed in BOD1-depleted cells (Figure 2A). Furthermore, loss of BOD1 neither increased MMC-induced micronuclei, nor engendered a cellular hypersensitivity to MMC or HU (Figures 2B-D). In addition, unlike BOD1 depletion, loss of BOD1L did not cause mitotic or spindle alignment defects (Figures 2E-F). Finally, immunostaining analyses of MMC-treated cells revealed that BOD1L depletion increases the proportion of micronuclei that are acentric (CENPA-negative) and that contain DNA double strand breaks (DSBs) (53BP1-positive), suggesting that these micronuclei originated from unrepaired DNA damage (Figure 3A). Together, these observations demonstrate that BOD1 and BOD1L perform separate roles in cell cycle regulation and genome maintenance respectively.

**BOD1L functions within the Fanconi Anaemia pathway**

Micronuclei are observed in the absence of several genome stability factors, although FA-deficient are especially prone to ICL-induced micronucleation (Naim and Rosselli, 2009a). It has been proposed that micronuclei arising in cells undergoing replication stress stem from a failure to complete timely DNA replication. This results in the persistence of under-replicated DNA in cells as they enter mitosis, which can manifest as UFBs, typically marked by PICH and flanked by FANCD2 foci (Chan et al., 2007; Chan et al., 2009). These can lead to chromosome breakage and
packaging of the damaged DNA into 53BP1 bodies visible in the subsequent G1 phase (Lukas et al., 2011).

We next determined the prevalence of late replicating DNA, UFBs and G1-phase 53BP1 bodies in BOD1L deficient cells following MMC exposure. Loss of BOD1L dramatically increased the percentage of mitotic cells positive for either FANCD2/PICH positive UFBs or for EdU foci following MMC exposure (Figures 3B-D). Consistent with this, we observed a significant rise in the number of 53BP1 G1 bodies in these cells, which was again more severe than depletion of FANCA alone (Figures 3E-F). Collectively, these data suggest that the micronuclei observed in BOD1L-deficient cells are due to a failure to correctly resolve replication stress.

FA cells exhibit chromosomal hypersensitivity to agents that induce ICLs, caused in part by the presence of under-replicated DNA, and exhibit chromatid breakage at specific loci, namely CFS (Barlow et al., 2013; Durkin et al., 2007; Schoder et al., 2010). Strikingly, loss of BOD1L resulted in catastrophic levels of chromosome breakage following MMC exposure, which was markedly more severe than FANCA loss (Figures 3G and S2A). In agreement with previous data, co-depletion of FANCA/BOD1L had no additional effect on genome instability. Furthermore, the majority of BOD1L-deficient cells showed evidence of chromosome breakage at the CFS locus FRA16D (Figure 3H). Importantly, genome stability in BOD1L-depleted cells was restored by the stable expression of murine Bod1L, which is resistant to siRNA-mediated degradation, in two independent HeLa cell clones (CFlap-mBod1L C1-4 and C5-20) (Figures S2B-D). Taken together, these observations clearly demonstrate that BOD1L functions to resolve replication stress, in conjunction with FA pathway components (Naim and Rosselli, 2009b).

Given that BOD1L is epistatic with a core FA pathway component, we evaluated the functional integrity of this pathway in the absence of BOD1L. The DNA damage-induced mono-ubiquitylation of FANCD2 is a central event within the FA pathway, and is often used as a marker of FA pathway integrity (Smogorzewska et al., 2007). Loss of BOD1L had no effect on the focal recruitment of FANCD2 to sites of MMC damage, nor its ability to be mono-ubiquitylated (Figures S2E-F), suggesting that BOD1L functions downstream of the FA core and FANCI/D2 complexes within the FA/HR pathway.
BOD1L depletion compromises the fidelity of DNA replication following replication stress

The cellular response to replication stress is primarily coordinated by the ATR kinase, which activates the intra-S phase checkpoint and protects stalled replication forks from collapse. Recent studies on ATR-deficient cells have demonstrated that fork protection is crucial to maintain CFS integrity (Koundrioukoff et al., 2013). Given that BOD1L-depleted cells exhibit CFS instability, this suggests that BOD1L may protect replication forks directly, in a similar fashion to ATR. We therefore hypothesised that loss of BOD1L would negatively impact S-phase regulation and/or replication fork dynamics upon replication stress.

Initially, we sought to determine the effect of depleting BOD1L on cell cycle progression. Compromising BOD1L expression had little effect on cell cycle progression in the absence of DNA damage (Figure 4A). However, consistent with a defect in resolving S-phase damage, cells lacking BOD1L rapidly accumulated in G2-phase following MMC exposure, with a concomitant reduction in mitotic index (Figures 4B and S3A-B); a phenotype reminiscent of FA cells (Akkari et al., 2001; Heinrich et al., 1998;). Next, to directly analyse the stability of on-going replication forks following HU treatment, we quantified the symmetry of sister replication forks originating from the same origin and travelling in opposite directions. Since sister forks typically display similar replication rates (Conti et al., 2007), marked fork asymmetry indicates that individual forks are more prone to stalling (Rodriguez-Lopez et al., 2002). Supportive of a role for BOD1L in promoting fork stability, we observed a significant increase in replication fork asymmetry in BOD1L depleted cells following HU treatment (Figure 4C), suggesting that damaged forks are slower to restart and/or are more susceptible to stalling in its absence.

We also observed a significant increase in new origin firing in response to both HU and MMC in cells lacking BOD1L, which was dependent on Cdk1/2 activity (Figures 4D-E and S3C-E). However, this origin firing was not due to defective ATR/Chk1 signalling, since BOD1L-depleted cells were proficient for Chk1 phosphorylation on both S317 and S345 in response to MMC (Figure 4F). This phenotype was also not present in cells depleted of BOD1, further strengthening the functional divergence of these proteins (Figure S3F).

Despite observing increased new origin firing and replication fork asymmetry in BOD1L depleted cells after replication stress, there was no concomitant reduction in the number of
restarted forks, nor any increase in fork stalling (first label terminations). One possible explanation was that new origins were firing proximal to stalled/collapsed (red only labelled) forks in BOD1L depleted cells, therefore artificially enhancing the quantification of restarted (red and green labelled) replication forks. To investigate this, we used a Cdk1/2 inhibitor to inhibit new origin firing in cells lacking BOD1L, and examined the impact on fork stalling/restart. Accordingly, we found that inhibition of Cdk1/2 activity during HU exposure ablated new origin firing, increased the prevalence of stalled replication forks, and decreased fork restart (Figure S3G), suggesting that BOD1L prevents fork stalling upon replication stress.

Together, these data suggest that, upon the induction of replication stress, a lack of BOD1L compromises fork stability and/or restart, which triggers dormant origin firing proximal to the stalled/damaged fork.

**BOD1L protects stalled forks from uncontrolled resection**

It is thought that uncontrolled origin firing in the absence of ATR leads to excessive ssDNA generation and exhaustion of cellular pools of RPA, which both cause irreversible fork collapse (Toledo et al., 2013). It is conceivable that global depletion of soluble RPA may also underlie the excessive chromosome breakage observed in BOD1L deficient cells, since they also exhibit increased origin firing, fork instability and defective fork restart. To investigate this, we first sought to determine levels of ssDNA present in BOD1L-depleted cells following MMC exposure. Loss of BOD1L resulted in a significant increase in RPA loading onto damaged chromatin compared to control cells (Figures 5A-B and S4A). Moreover, ablation of BOD1L expression significantly enhanced the formation of MMC-induced native BrdU foci (Figures 5C and S4B), consistent with increased ssDNA generation in these cells. However, in contrast to ATR-deficient cells (Toledo et al., 2013), RPA over-expression had no effect on either new origin firing or chromosomal instability in the absence of BOD1L (Figures S4C-E). In addition, it is clear that the ATR-Chk1 pathway is functional in BOD1L deficient cells (see Figure 4F). Therefore, although cells lacking ATR or BOD1L display phenotypic similarities, it appears that the mechanisms underlying replication fork stalling/collapse differ.
It has been demonstrated that loss of FA pathway components such as BRCA2 and FANCD2 leads to nucleolytic degradation of stalled replication forks, rendering them non-permissive for repair by HR (Schlacher et al., 2011; 2012). This excessive fork resection underlies the increased chromosome breakage exhibited by BRCA2-null cells. The nucleases Mre11 and/or DNA2 appear to perform this uncontrolled resection; inhibition of Mre11 can alleviate fork degradation in BRCA2 deficient cells (Schlacher et al., 2011), and depletion of DNA2 rescues the hypersensitivity of FANCD2 deficient cells to cisplatin (Karanja et al., 2014). To investigate whether similar mechanisms underlie the phenotypes of BOD1L-deficient cells, we examined levels of MMC-induced RPA2 phosphorylation on S4/S8, a well-established marker of DNA resection. Depletion of BOD1L (but not BOD1) resulted in elevated levels of RPA2-S4/8 phosphorylation following MMC treatment (Figures 5D-F and 2A), which could be restored to control levels by the expression of CFLap-mBod1L (Figure S4F). Hyper-phosphorylation of RPA2 was also observed in BOD1L-deficient cells following exposure to HU, indicating that this defect is not restricted to MMC-induced ICLs (Figure S4G). Therefore, these data suggest that BOD1L functions to suppress resection. Consistent with this, we observed an increased localisation of BOD1L to damaged forks undergoing resection (Figure 5G).

To confirm that uncontrolled resection in BOD1L depleted cells occurs specifically at replication forks, we used the approach described by Schlacher et al. (2011) to monitor degradation of nascent DNA. In line with previous observations, loss of BRCA1 or BRCA2 increased the degradation of newly synthesized DNA at forks (apparent as a decreased IdU:CldU ratio; Figure 6A and S5A-B). Interestingly, cells lacking BOD1L exhibited similar degradation of stalled replication forks. Critically, this was epistatic with either BRCA1 or BRCA2 depletion, suggesting that BOD1L and BRCA1/2 function within the same pathway to protect replication forks. In support, BRCA2 and BOD1L co-depletion had no additional effect on cellular hypersensitivity to MMC or RPA2 hyper-phosphorylation compared to loss of the individual genes alone (Figure S5C-E). Finally, BOD1L co-immunoprecipitated with the fork protection factors FANCD2 and BRCA2 (Figure 6B). Together, this provides strong evidence that BOD1L plays a vital role in preventing unconstrained resection at stalled forks, in concert with FANCD2 and BRCA1/2.
We next sought to ascertain whether the increased resection seen in cells devoid of BOD1L was mediated by Mre11, DNA2 and/or Exo1; three nucleases implicated in fork resection. In line with the study by Karanja et al. (2014), co-depletion of DNA2, but not Exo1, completely repressed MMC-induced RPA2 S4/8 hyper-phosphorylation observed in cells lacking BOD1L (Figures S5F-G). Furthermore, the over-resection of stalled forks was completely abolished by co-depletion of DNA2 with BOD1L. However, in contrast to previous findings with BRCA1/2 and FANCD2 (Schlacher et al., 2011), inhibition of Mre11 by Mirin was unable to rescue nucleolytic fork degradation in the absence of BOD1L (Figures 6C and S5H). Moreover, the combined loss of DNA2 and BOD1L restored the MMC-induced micronuclei and chromosome damage to normal levels (Figure 6D-E). This demonstrates that the severe genome instability in cells lacking BOD1L arises from uncontrolled DNA2-dependent resection of damaged forks.

**BOD1L stabilises Rad51 at damaged replication forks by suppressing anti-recombinogenic pathways**

The strand exchange protein Rad51 is best known as a principal effector of HR, but it also plays a central role in stabilising/promoting the restart of damaged replication forks (Petermann et al., 2010; Costanzo, 2011). Accordingly, the excessive fork degradation observed in BRCA2 or FANCD2 deficient cells is restored by overexpressing an ATPase-dead Rad51 mutant, which stabilises Rad51 nucleofilaments on ssDNA by preventing its ATP-dependent dissociation (Schlacher et al., 2011; 2012). Thus, the loading of Rad51 onto stalled forks prevents uncontrolled nucleolytic activity.

To investigate whether a defect with Rad51 function underlies the excessive fork resection observed in the absence of BOD1L, we exposed BOD1L-depleted cells to MMC, and then monitored the accumulation/retention of Rad51 at sites of damage by immunofluorescence. Notably, MMC-induced Rad51 foci formation was severely compromised in BOD1L-depleted cells (Figure 6F). This was observed with 4 different BOD1L siRNA sequences, and was not due to any alteration in Rad51 protein expression (Figures S5I-J). Moreover, the defective focal recruitment of Rad51 (Figure S6A) upon damage could be restored by the expression of CFlap-mBod1L (Figures S6B-C). In keeping, Rad51 also failed to load efficiently onto MMC-damaged chromatin.
in cells lacking BOD1L (Figure 6G). Consistent with this, BOD1L-depleted cells exhibited increased numbers of MMC-induced radial chromosomes, and a concomitant decrease in the frequency of MMC-induced SCEs (Figures S6D-E). Strikingly, the formation of IR-induced Rad51 foci at DSBs was unaffected in BOD1L-depleted cells (Figure S6F), suggesting that our observations were not due to a global defect in Rad51 loading per se, but rather an inability to localise/stabilise Rad51 to stalled replication forks.

Conceivably, a defect in recruiting Rad51 to stalled forks may be due to either a failure to properly load Rad51 onto ssDNA, or an inability to maintain loaded Rad51 on chromatin. To investigate the former possibility, we examined the impact of BOD1L depletion on the recruitment of BRCA1, BRCA2 and PALB2, which are essential for Rad51 loading to ICLs (Bhattacharyya et al., 2000; Godthelp et al., 2006; Xia et al., 2007). Cells lacking BOD1L exhibited no observable defects in the re-localisation of BRCA1, BRCA2 or GFP-PALB2 to foci following exposure to MMC (Figures 6H and S6G-I), suggesting that BOD1L may instead be required to stabilise/retain Rad51 on damaged chromatin.

Proteins involved in Rad51 filament dissolution play a vital role in controlling HR and maintaining genome stability. Of these, the RecQ-like helicases BLM and RECQL5, and the F-box-containing helicase Fbh1 are the best studied: all three suppress Rad51-dependent HR, particularly in response to replication stress. We speculated that the phenotypes observed in BOD1L-deficient cells following MMC exposure may arise from the uncontrolled activity of one or more of these anti-recombinase(s). We therefore siRNA-depleted BOD1L in combination with BLM, Fbh1 or RECQL5, and monitored the levels of MMC-induced RPA S4/S8 phosphorylation and Rad51 foci formation. Strikingly, loss of either Fbh1 or BLM (but not RECQL5) reduced MMC-induced RPA S4/S8 phosphorylation and restored Rad51 focus formation in BOD1L-depleted cells (Figures 7A-B and S7A-C). Consistent with this, co-depletion of Fbh1 in BOD1L-depleted cells restored MMC-induced loading of Rad51 onto chromatin (Figure S7D). However, depletion of Fbh1 or BLM was unable to restore Rad51 focus formation in the absence of BRCA2, suggesting that BOD1L acts downstream of BRCA2 to control Rad51 (Figure S7E). Depleting Fbh1 or BLM expression also partially alleviated the over-resection of stalled replication forks observed in cells lacking BOD1L, in keeping with the notion that Rad51 suppresses aberrant fork resection.
Strikingly, RECQL5 depletion further increased fork resection in the absence of BOD1L, indicating that these two factors act in separate pathways (Figures 7C and S7F). Lastly, ablating Fbh1 or BLM expression also restored genome stability in cells depleted of BOD1L (Figures 7D and S7G). Loss of RECQL5, however, had no restorative impact on MMC-induced chromosomal instability. Finally, and in keeping with a role for BOD1L in stabilising Rad51 by counteracting BLM, both BLM and Rad51 could be co-immunoprecipitated with BOD1L or CFlap-mBod1L (Figure 7E and S7H).

Taken together, these data demonstrate that BOD1L functions to restrain the pro-resection and anti-recombinogenic functions of BLM/Fbh1 towards Rad51, thereby stabilising Rad51 on chromatin and promoting HR-dependent repair of damaged replication forks. In the absence of BOD1L, damaged replication forks undergo deleterious DNA2-dependent nucleolytic resection, which compromises fork repair/restart and leads to catastrophic genome instability (Figure 7F).
DISCUSSION

The ability to efficiently resolve replication stress is vital to maintain genome stability. In this study, we have identified BOD1L as a factor associated with newly replicated chromatin that functions to prevent catastrophic DNA damage induced by replication stress by protecting damaged replication forks from promiscuous nucleolytic degradation.

Loss of Rad51-mediated fork protection underlies uncontrolled fork resection and genome instability in BOD1L deficient cells

Rad51-dependent HR plays an essential role to stabilise, protect and promote the restart of stalled or damaged replication forks. Central to this process is the BRCA1/BRCA2/PALB2-dependent loading of Rad51 onto RPA-coated ssDNA generated at such forks (Costanzo, 2011). Rad51 fork loading stabilises replication fork intermediates and prevents deleterious nucleolytic processing (Petermann et al., 2010; Schlacher et al., 2011; 2012). Loss of this protective activity cripples the repair/restart of damaged forks and compromises genomic integrity.

We observed that BOD1L depleted cells exhibit increased fork degradation in a manner comparable to BRCA1/BRCA2 deficient cells. This suggests that defects in the recruitment and/or stabilisation of Rad51 allow degradation of damaged forks in BOD1L-deficient cells. Yet, in marked contrast to the complete loss of BRCA2 or PALB2 (Yuan et al., 1999; Xia et al., 2006; Zhang et al., 2009), loss of BOD1L does not impact on the recruitment of Rad51 to DSBs induced by IR. This implies that the function of BOD1L in regulating Rad51 in response to genotoxic damage is restricted to lesions that cause replication stress.

The repair and restart of forks requires the tightly regulated processing of replication damage (such as ICLs) by several different nucleases. Whilst such nucleolytic processing is important for cell survival, uncontrolled activity of these nucleases is also detrimental to genomic integrity (Adamo et al., 2010; Karanja et al., 2014). In keeping with this, uncontrolled resection of damaged forks and increased genomic instability observed in the absence of BOD1L was completely alleviated by co-depletion of DNA2. In contrast, inhibition of Mre11 activity with Mirin had no effect on the degradation of stalled replication forks in the absence of BOD1L. Since both BRCA2 and FANCD2 suppress the activity of Mre11 at stalled forks (Schlacher et al., 2011; 2012;
Ying et al., 2012), our data suggests that BOD1L acts independently to inhibit aberrant DNA2 activity. Based on this, loss of BOD1L and BRCA2 should further increase fork resection, rather than exhibit the epistatic relationship we observed. Although the underlying reason is unclear, we postulate that nucleolytic degradation of a damaged fork by one nuclease prohibits further processing by other nucleases.

Interestingly, since BOD1L co-immunoprecipitated with both BRCA2 and FANCD2 in unperturbed cells, this raises two intriguing possibilities: that multiple fork protection factors act to individually block the activities of different nucleases towards replication forks, and that they may exist in a single complex.

Mechanisms for BOD1L in stabilising Rad51 on damaged chromatin

Our data demonstrates that loss of BOD1L is epistatic with deficiencies in BRCA1/BRCA2, although the phenotypes observed in the absence of BOD1L cannot be explained by an inability to recruit BRCA1, BRCA2 or PALB2 to sites of replication stress. Instead, co-depletion of BOD1L with the anti-recombinogenic helicases Fbh1 or BLM restored Rad51 focal recruitment, stalled replication fork resection and genome stability. Thus, chromatin-bound Rad51 may be more susceptible to anti-recombinases, and/or Rad51 nucleofilaments may be more unstable, in the absence of BOD1L. Importantly, Fbh1 or BLM knockdown failed to recover MMC-induced Rad51 foci formation in BRCA2-depleted cells, suggesting that BOD1L acts downstream of BRCA2/PALB2 (see Figure S6F). Moreover, BOD1L associates with Rad51, suggesting that it may stabilise Rad51 directly. Together, our data suggest that BRCA2 and BOD1L function independently in a common pathway to protect replication forks, and that BOD1L acts in a similar manner to the C-terminus of BRCA2 (Esashi et al., 2007; Schlacher et al., 2011), i.e. promoting Rad51 nucleofilament stability. Intriguingly, co-depletion of BOD1L with another anti-recombinogenic helicase, RECQL5, failed to restore Rad51 foci formation, and actually increased/accelerated fork degradation. This is in line with recent data demonstrating that the combined loss of FA proteins with RECQL5 is additive in terms of fork degradation, and that BLM and RECQL5 have divergent functions in the absence of an intact FA pathway (Kim et al., 2015).
It is unclear why depletion of two independent factors (namely BLM or Fbh1) is able to compensate for a lack of BOD1L, although BLM and Fbh1 have partially redundant functions in DT40 cells (Kohzaki et al., 2007). Whilst Fbh1 and BLM both have pro- and anti-recombinogenic activities (Bugreev et al., 2007; Fugger et al., 2009), BLM can displace Rad51 from ssDNA, and can also potentiate HR through its ability to stimulate DNA2-dependent end-resection by binding to RPA (Chen et al., 2013; Xue et al., 2013; Sturrzenegger et al., 2014). It is possible that loss of BLM activity in BOD1L/BLM knockdown cells has two effects: (1) increases Rad51 filament stability and; (2) compromises DNA2-dependent resection of damaged forks, the latter of which causes the genome instability apparent in BOD1L deficient cells.

Currently it is unknown whether BOD1L influences the activity of these anti-recombinases directly or controls their access to the damaged replication fork and/or the Rad51 filament itself. Given that BOD1L and BLM co-associate, it is tempting to speculate that BOD1L regulates BLM activity directly. Alternatively, since the Rad51 paralogues stabilise Rad51 nucleofilaments by blocking the translocase activities of anti-recombinogenic helicases (Amunugama et al., 2013; Liu et al., 2011), BOD1L may act in an analogous fashion to regulate access of BLM/Fbh1 to Rad51, ultimately stabilising Rad51 nucleofilaments at damaged replication forks. As a consequence, ablating BOD1L could promote uncontrolled BLM-DNA2-dependent resection, and allow BLM/Fbh1-dependent dissolution of Rad51 filaments.

**BOD1L functions in the latter stages of the FA/HR pathway**

The phenotypic similarities between BOD1L-deficient cells and FA-defective cells, particularly after ICL induction, suggest that BOD1L functions as part of the FA/HR pathway. Indeed, loss of BOD1L and core/downstream FA components (namely FANCA and BRCA2) are epistatic for MMC hypersensitivity and fork protection. In further support, the increased fork resection apparent in both BOD1L-deficient and FANCD2-null cells is attributable to the nucleolytic activity of DNA2 (Karanja et al., 2014). However, since BOD1L is not required for mono-ubiquitylation or relocalisation of FANCD2 to sites of DNA damage, and also that the chromatin localisation/retention of Rad51 is unaffected in cells lacking FA core components or FANCD2/I (Ohashi et al., 2005; Godthelp et al., 2006), this indicates that BOD1L functions in the latter stages
of the FA pathway, downstream of FANCD2/I. This also suggests that fork protection mechanisms independent of Rad51-loading (but perhaps dependent on Rad51 activity) also exist.

**Increased origin firing contributes to genome instability in BOD1L deficient cells**

We have shown that cells depleted of BOD1L exhibit increased new origin firing following the induction of replication stress. We hypothesise that this elevated origin firing is a cellular response to an inability to complete DNA replication, caused by the uncontrolled resection of stalled forks due to a failure to stabilise Rad51. This results in elevated levels of mitotic replication, UFBs, G1 53BP1 bodies and severe chromosomal instability.

Whether Rad51 defects alone promote new origin firing is currently unclear. Increased new origin firing does not occur in human cells depleted of Rad51 or in BRCA2-null CHO cells following HU (Petermann *et al.*, 2010; Jones *et al.*, 2014), but increased new origin firing has been shown in BLM-deficient cells and those lacking PALB2 (Davies *et al.*, 2007; Nikkila *et al.*, 2013). It therefore remains to be determined whether the inability of BOD1L-depleted cells to retain Rad51 at stalled replication forks contributes to the increase in origin firing. In spite of this, we predict that the increased origin firing in BOD1L deficient cells could contribute to genome instability, perhaps due to collisions between newly fired origins and damaged forks lying in close proximity.

**Summary**

Taken together, our data leads us to propose the following model (*Figure 7F*): BOD1L forms an essential component of the fork protection machinery. Upon stalling of a replication fork (for example by an ICL), limited nucleolytic resection allows Rad51-dependent HR and repair/restart of the stalled fork. BOD1L acts to stabilise Rad51 at such structures by protecting Rad51 nucleofilaments from the activities of Fbh1/BLM. In the absence of BOD1L, Rad51 is displaced from ssDNA by Fbh1/BLM, rendering the fork susceptible to uncontrolled resection by DNA2, and leading to catastrophic genome instability, in part mediated by the presence of under-replicated DNA.
EXPERIMENTAL PROCEDURES

Cell culture and generation of cell lines

A549, HeLa, HeLa S3, H1299 and HeLa-FUCCI cells were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum (FBS) (Gibco) and penicillin/streptomycin. HeLa-CFlap-BOD1L and U-2-OS SUPER-RPA cells were cultivated as above in the presence of 200 µg/ml Geneticin. U-2-OS and U-2-OS-PALB2-GFP cells were cultured in McCoys 5A medium, supplemented with 10% FBS and penicillin/streptomycin. DT40 cells were cultured in RPMI 1640 medium (Invitrogen) supplemented with 7% FBS, 3% chicken serum, and 10 µM β-mercaptoethanol. Further details of DT40s, HeLa-CFlap-mBOD1L cells, siRNA transfections and clonogenic survival assays are given in the Extended Experimental Procedures.

iPOND

iPOND was performed on HeLa S3 as described previously (Sirbu et al., 2013) with some modifications to allow for improved detection of high molecular weight proteins, which are described in Extended Experimental Procedures. In brief, newly synthesized DNA was labelled with 10µM EdU, cells were fixed in 1% formaldehyde, permeabilised and the Click reaction was performed using Azide-PEG (3+3)-S-S-Biotin Conjugate (Click ChemistryTools). Following sonication, EdU labelled DNA was precipitated using Streptavidin beads and eluted in buffer containing DDT.

Statistical analyses

Differences in survival assays were analysed by two-way ANOVA. Statistical differences in all cases were determined by Student’s t-test, except for fork asymmetry, which was analysed by Mann-Whitney rank sum test. In all cases: NS = p>0.05; * = p<0.05; ** = p<0.01; *** = p<0.001.
AUTHOR CONTRIBUTIONS
MRH, JJR and GSS designed the study, performed experiments and wrote the manuscript. AW performed iPOND. VB made HeLa-CFlap-mBOD1L cells and performed CFlap IPs. ANB and JN created BOD1L-null DT40s. ESM and AZ performed experiments and created reagents. ELR assisted with DNA combing. ND performed FISH. TS, SJB and WN supervised and advised on experiments. All authors contributed to manuscript revisions.

ACKNOWLEDGEMENTS
We are extremely grateful to Hongtao Yu, James Hsieh, Luis Toledo, Ross Warrington and Fumiko Esashi for valuable reagents. We thank Aga Gambus, Roger Grand, Eva Petermann and Malcolm Taylor for invaluable discussions. MRH, ESM and GSS are funded by a CR-UK Senior Fellowship (C17183/A13030). JJR is funded by the University of Birmingham and an MRC project grant (MR/M009882/1). AB, AW, JN and WN were funded by Worldwide Cancer Research and MRC Senior Non-Clinical Fellowships awarded to WN. AZ is funded by Worldwide Cancer Research (13-1012). ELR is funded by an MRC Ph.D. studentship. ND and TS are funded by a Leukemia and Lymphoma Research program grant (11045). VB is funded by the ERC and SJB is supported by the Wellcome Trust, CR-UK and ERC.
REFERENCES


20


FIGURE LEGENDS

Figure 1: BOD1L is present at newly-replicated DNA, and ensures cellular viability after replication stress. (A) Upper: Schematic of human BOD1L and BOD1 domain structure and ATM/ATR phosphorylation sites. Lower: Amino acid sequence alignment of BOD1L and BOD1. Conserved residues (red) and similar residues (+) are denoted. (B) Immunoblotting of EdU-coprecipitates from HeLa S3 cells. (C-D) HeLa cells were transfected with the indicated siRNAs, and pulsed with 10 µM EdU for 10 minutes before pre-extraction/fixation. EdU incorporation was visualised with Click-iT chemistry, and detection of protein-protein associations were performed using a fluorescently labelled PLA probe along with the indicated antibodies. (C) shows quantification of PLA signals/nucleus from at least 100 cells (n = 3; lines denote mean values), and representative images are shown (D). Scale bars = 10 µm. (E) HeLa nuclear cell extracts were subjected to IP with the indicated antibodies, and inputs and immunoprecipitates were analyzed by immunoblotting. Blots originate from a single gel. A white line denotes removal of irrelevant lanes. (F) The survival of HeLa cells transfected with the indicated siRNA following exposure to mitomycin C (MMC) or hydroxyurea (HU) was assessed by colony survival assay. (G) Micronuclei formation following DNA damage was assessed in siRNA-transfected HeLa cells by fluorescence microscopy. Plots (F)-(G) represent mean data from four independent experiments; error bars = SEM. See also Figure S1.

Figure 2: BOD1L is functionally distinct from BOD1. (A) Whole cell extracts (WCE) of HeLa cells transfected with the indicated siRNA were analysed by immunoblotting after exposure to 50 ng/ml MMC for the denoted times. (B) HeLa cells from (A) were exposed to 50 ng/ml MMC for 24 h, and micronuclei enumerated. (C-D) The survival of HeLa cells transfected with the indicated siRNA was assessed by colony survival assay as in Figure 1F. (E-F) Untreated HeLa cells from (A) were immunostained with antibodies to α-tubulin and PCNT1, and the percentage of mitotic cells in each stage of mitosis (E), or their ability to form centrosomes (F), was analysed by immunofluorescence. Scale bars = 10 µm. Data represent mean ± SEM of three independent experiments.
Figure 3: BOD1L knockdown leads to problematic resolution of replication stress. (A) The percentage of micronuclei positive for either 53BP1 or CENPA was quantified by immunofluorescence microscopy in HeLa cells transfected with indicated siRNAs after exposure to 50 ng/ml MMC for 24 h. (B) The percentage of mitotic cells with PICH-positive UFBs was quantified in transfected HeLa cells after exposure to 250 ng/ml MMC for 3 h and release into fresh media for 36 h. (C) The mean percentage of PICH-positive UFBs with terminal FANCD2 foci in mitotic cells from (B) is indicated. (D) Cells from (B) were pulsed with 10 µM EdU for 45 minutes before fixation. Mitotic EdU incorporation was visualised with Click chemistry labelling, and the mean number of EdU foci per mitotic cell, and merged representative images, are shown. Scale bars = 10 µm. (E-F) HeLa-FUCCI cells were siRNA-transfected, and exposed to 50 ng/ml MMC for 24 h. (E) WCE were analysed by immunoblotting. Loading control denotes a non-specific protein detected by anti-BOD1L antibody. (F) The number of 53BP1 bodies in RFP-positive (i.e. G1) cells was enumerated. (G) Damage to metaphase chromosomes from HeLa cells subjected to the indicated siRNAs was determined by Geimsa staining and light microscopy. Upper: Graphs integrate data from three independent experiments (n = 150; lines denote mean values). Lower: Representative metaphase spreads are shown, with chromosomal damage denoted by arrowheads. (H) Cells from (G) were analysed by FISH using probes against FRA16D. Plots represent mean ± SEM of three independent experiments. See also Figure S2.

Figure 4: BOD1L knockdown increases origin firing after replication stress and destabilises replication forks. (A-B) The cell cycle profiles of HeLa cells subjected to the indicated siRNAs were analysed by flow cytometry. Representative profiles from untreated cells (A) or after exposure to 250 ng/ml MMC for 3 h (B) are shown. (C-D) DNA fibre analysis of HeLa cells transfected with the indicated siRNAs. Cells were pulsed with CldU, exposed to 2 mM HU for 2 h, and pulsed with IdU. Plots indicate ratios of left/right fork lengths of bidirectional replication forks travelling from a single origin. Lines denote median ratios (C). DNA fibres were enumerated, and the percentage of new origins (IdU-labelled only) is displayed (D). (E) Transfected cells from (C) were exposed to 50 ng/ml MMC for 24 h, and pulsed sequentially with CldU and IdU. DNA fibres were quantified, and the percentage of new origins is displayed. (F) WCE of HeLa cells transfected as above and
exposed to MMC for the indicated times were analysed by immunoblotting. *Chronic = 50 ng/ml MMC. **Acute = 250 ng/ml MMC for 3h followed by wash out. Times for acute exposure indicate h post washout. Plots represent mean ± SEM of at least three independent experiments. See also Figure S3.

Figure 5: BOD1L prevents excessive ssDNA formation and RPA2 hyper-phosphorylation after MMC exposure. (A) Soluble and chromatin fractions of U-2-OS cells transfected with the indicated siRNAs, and exposed to 100 ng/ml MMC for 24 h, were analysed by immunoblotting. Loading control denotes a non-specific protein detected by anti-BOD1L antibody. Blots originate from a single gel. A white line denotes removal of superfluous lanes. (B) RPA foci formation was analysed in HeLa cells transfected as above and exposed to 50 ng/ml MMC for the denoted times. (C) Native BrdU foci formation in U-2-OS cells by fluorescence microscopy. Cells were transfected with the indicated siRNAs, and BrdU added for 24 h. Cells were exposed to 50 ng/ml MMC for a further 24 h in the presence of BrdU, and immunostained with antibodies to BrdU and γH2AX. Foci formation was analysed (see Figure S4B), and enumerated. (D) WCE of HeLa cells transfected as in (B), and exposed to MMC for the indicated times, were analysed by immunoblotting. *Chronic = 50 ng/ml MMC. **Acute = 250 ng/ml MMC for 3h followed by wash out. Times for acute exposure indicate h post washout. (E) Phospho-RPA (S4/S8) and RPA foci formation in transfected HeLa cells exposed to 50 ng/ml MMC for 24 h. (F) The number of double positive cells from (E) was enumerated. (G) Detection of protein-protein interactions was performed using a fluorescently labelled PLA probe in HeLa cells from (B). The plot shows quantification of PLA signals/nucleus from at least 100 cells (n=3; lines denote mean values), and representative images are shown. Plots represent mean ± SEM of three independent experiments. Scale bars = 10 μm. See also Figure S4.

Figure 6: BOD1L is required to suppress aberrant fork resection after replication stress, and is required for efficient Rad51 chromatin loading. (A) Fork degradation was analysed in U-2-OS cells. Cells were transfected with the indicated siRNAs, pulsed for 20 min each with CldU and...
IdU, and exposed to 4 mM HU for 5 h. DNA was visualised with antibodies to CldU and IdU, and plots denote the average ratios of IdU:CldU label lengths from three independent experiments. Arrows indicate mean values (see Figure S5B). (B) HeLa nuclear cell extracts were subjected to IP with the denoted antibodies, and inputs and immunoprecipitates were analyzed by immunoblotting. Blots originate from a single gel. A white line denotes removal of irrelevant lanes. (C) Fork degradation in U-2-OS cells transfected and treated as in (A) was analysed. Where appropriate cells were treated with Mirin for the duration of the HU pulse (see Figure S5H). (D) Micronuclei formation was quantified in HeLa cells transfected with the indicated siRNAs and treated with 50 ng/ml MMC for 24 h. (E) Damage to metaphase chromosomes from cells (D) was analysed (n = 150; lines denote mean values). (F) Rad51 foci formation was analysed in siRNA-transfected HeLa cells, and exposed to 50 ng/ml MMC for the indicated times. Scale bars = 10 µm. (G) Soluble and chromatin fractions from Figure 5A were analysed by immunoblotting. (H) Foci formation of BRCA1 and BRCA2 was analysed in HeLa cells from (F). Alternatively, U-2-OS-PALB2-GFP cells were transfected with the indicated siRNAs, exposed to 50 ng/ml MMC for 24 h, and fixed. In both cases mean percentage of cells with foci are shown (see Figures S6G-I). Plots (D-H) represent mean ± SEM of three independent experiments. See also Figures S5 and S6.

Figure 7: BOD1L stabilises Rad51 chromatin loading to prevent excessive replication fork resection. (A-B) RPA2/phospho-RPA2 S4/S8 (A) or Rad51 (B) foci formation was analysed in HeLa cells transfected with the indicated siRNAs and exposed to 50 ng/ml MMC for 24 h. Scale bars = 10 µm. (C) Fork degradation was assessed in U-2-OS cells transfected with the indicated siRNAs as described in Figure 6A (see also Figure S7F). (D) Damage to metaphase chromosomes in HeLa cells from (A) was analysed (n = 100; lines denote mean values). (E) HeLa nuclear cell extracts subjected to IP with the indicated antibodies, and inputs and immunoprecipitates were analyzed by immunoblotting. Blots originate from a single gel. A white line denotes removal of irrelevant lanes. Plots (C-D) represent mean ± SEM of three independent experiments. (F) Model of BOD1L function to promote Rad51 nucleofilament stability and prevent uncontrolled resection of replication forks. Upon replication fork stalling, forks undergo minimal nucleolytic processing (i), allowing Rad51 loading/protection by BRCA1/BRCA2/PALB2 (ii). BOD1L
acts to stabilise Rad51 nucleofilaments by protecting them from the activities of BLM/Fbh1 (iii), thus preventing uncontrolled resection and allowing Rad51-mediated repair/restart of forks, ultimately maintaining genome stability. In the absence of BOD1L, BLM/Fbh1 act to remove Rad51 from such forks exposing them to uncontrolled DNA2-dependent processing (iv). To compensate for this fork instability, increased new origin firing occurs. When combined with uncontrolled resection of replication forks, this leads to catastrophic genome instability (v). See also Figure S7.
Figure 1

A

BOD1H

BOD1L

BOD1

N

1

57

161

C

1

5

10

αPCNA

αBOD1L

Con

αPCNA

Con

PLA signals/EdU-positive nucleus

15

20

25

30

Dose of HU (mM)

Con siRNA

BOD1L siRNA

FANCA siRNA

FANCA+BOD1L siRNA

FANCA/BOD1L siRNA

B

Click

Elution

Input

- +

- +

BOD1L

MRE11

RPA2

PCNA

C

30

25

20

15

10

5

0

PLA signals/EdU-positive nucleus

siRNA

Con

BOD1L

Con

αPCNA + αBOD1L

αPCNA

D

siRNA

EdU

DAPI + PLA

EdU

αPCNA + αBOD1L

αPCNA

E

IB

IP

5% Input

α-IgG

α-BOD1L

IB

BOD1L

MCM2

MCM7

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB

IB
Figure 2

A

<table>
<thead>
<tr>
<th>siRNA</th>
<th>Control</th>
<th>BOD1L</th>
<th>BOD1</th>
<th>BOD1L/BOD1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time (h) after MMC</td>
<td>0 24 48</td>
<td>0 24 48</td>
<td>0 24 48</td>
<td>0 24 48</td>
</tr>
</tbody>
</table>

B

Number of micronuclei/cell

C

% Cell Survival vs. HU (mM)

D

% Cell Survival vs. MMC (ng/ml)

E

% of mitotic cells vs. Phases

F

DAPI, α-Tubulin, PCNT1
Figure 3

A

% of micronuclei

53BP1-positive MN
CENPA-positive MN

siRNA Con BOD1L Con BOD1L
Untaxed + MMC

B

% of metaphases with UFBs

Con siRNA BOD1L siRNA
Untaxed + MMC

C

% of mitotic cells with FANCD2-positive UFBs

Con siRNA BOD1L siRNA
Untaxed + MMC

D

% of mitotic cells

EdU foci/cell

Con siRNA BOD1L siRNA
0 1 2-5 5-10 10+

E

% of mitotic cells with FANCD2-positive UFBs

Con siRNA BOD1L siRNA
Untaxed + MMC

F

% of G1 cells

Number of 53BP1 bodies/cell

1-2 3-4 5-6 7-8 9+

G UPPER

Chromatid gaps/breaks per metaphase

Con siRNA BOD1L FANCA BOD1L/FANCA
+ MMC

H

% of G1 cells

Number of 53BP1 bodies/cell

1-2 3-4 5-6 7-8 9+

Lower Control siRNA + MMC BOD1L siRNA + MMC
Figure 4

A

<table>
<thead>
<tr>
<th>Treatment</th>
<th>DNA Phase Distribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Con siRNA</td>
<td>G1:57.7%, S:16.4%, G2/M:23.9%</td>
</tr>
<tr>
<td>BOD1L siRNA</td>
<td>G1:54.5%, S:18.6%, G2/M:25.1%</td>
</tr>
</tbody>
</table>

B

Time (h) post MMC: 0, 24, 48

C

Left fork length/right fork length (ratio)

D

% of all CldU labelled

E

% of all CldU labelled

F

<table>
<thead>
<tr>
<th>Time (h) after MMC</th>
<th>Control siRNA</th>
<th>BOD1L siRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chronic*</td>
<td>Acute**</td>
</tr>
<tr>
<td></td>
<td>Chronic*</td>
<td>Acute**</td>
</tr>
</tbody>
</table>

- CHK1 S345-P
- CHK1 S317-P
- CHK1
Figure 5

A

B

C

D

E

F

G
Figure 6

A) Graph showing the IdU:CldU ratio and % of forks for different conditions: Con siRNA + HU, BRCA2 siRNA + HU, BOD1L siRNA + HU, BOD1L/BRCA2 siRNA + HU.

B) Western blot analysis for BOD1L, BRCA2, FANCD2, and RPA2 with IP (immunoprecipitation) and IgG controls.

C) Graph showing the IdU:CldU ratio and % of forks for different conditions: Con siRNA + HU, BOD1L siRNA + HU, BOD1L/DNA2 siRNA + HU, BOD1L siRNA + Mirin + HU.

D) Bar graph showing the % of cells with different numbers of micronuclei/cell for Control siRNA + MMC, BOD1L siRNA + MMC, DNA2 siRNA + MMC, and BOD1L/DNA2 siRNA + MMC.

E) Box plot showing chromatid gaps/breaks per metaphase for different siRNA conditions: Con, BOD1L, DNA2, BOD1L/DNA2 + MMC.

F) Time course experiment showing DAPI staining over 0, 24, and 48 hours for Control siRNA + RAD51, BOD1L siRNA + RAD51.

G) Western blot analysis for BOD1L, RAD51, H2A, with loading controls for Con siRNA and BOD1L siRNA, showing Soluble and Chromatin conditions with and without MMC.

H) Bar graph showing % of cells with nuclear foci for Con siRNA + MMC and BOD1L siRNA + MMC.
Figure 7

A

P-RPA S4/8  RPA  DAPI
Con
BOD1L
FBH1
BOD1L/FBH1
BLM
BOD1L/BLM
RECQL5
BOD1L/RECQL5

B

RAD51  DAPI

C

% of forks

0 0.5 1.0 1.5 2.0
IdU:CldU ratio

0 5 10 15 20 25 30

Con siRNA + HU
BOD1L siRNA + HU
BOD1L/FBH1 siRNA + HU
BOD1L/BLM siRNA + HU
BOD1L/RECQL5 siRNA + HU

D

Chromatid gaps/breaks per metaphase

siRNA

Con  BOD1L  BLM  BOD1L/BLM  FBH1  BOD1L/FBH1  RECQL5  BOD1L/RECQL5

+ MMC

E

IB

5% Input  α-IgG  α-BOD1L

BOD1L  BLM

F

(i) Fork stalling (e.g., ICL)

(ii) BRCA1  BRCA2  PALB2

(iii) RAD51 stabilisation

(iv) Genome instability

(v) New origin firing

Fork recovery/repair by HR

Maintenance of genome stability

Normal resection

Uncontrolled resection
Figure S1

A

<table>
<thead>
<tr>
<th>Protein ID</th>
<th>No. of peptides</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPCNA</td>
<td>9</td>
</tr>
<tr>
<td>Pol &amp; p66 subunit</td>
<td>3</td>
</tr>
<tr>
<td>Pol &amp; p50 subunit</td>
<td>7</td>
</tr>
<tr>
<td>Pol &amp; Cat. subunit</td>
<td>20</td>
</tr>
<tr>
<td>Pol &amp; aB subunit</td>
<td>3</td>
</tr>
<tr>
<td>Pol &amp; cat. subunit</td>
<td>9</td>
</tr>
<tr>
<td>RFC1</td>
<td>5</td>
</tr>
<tr>
<td>RFC2</td>
<td>5</td>
</tr>
<tr>
<td>RFC3</td>
<td>6</td>
</tr>
<tr>
<td>RFC4</td>
<td>10</td>
</tr>
<tr>
<td>RFC5</td>
<td>7</td>
</tr>
<tr>
<td>MCM2</td>
<td>21</td>
</tr>
<tr>
<td>MCM3</td>
<td>22</td>
</tr>
<tr>
<td>MCM4</td>
<td>26</td>
</tr>
<tr>
<td>MCM6</td>
<td>17</td>
</tr>
<tr>
<td>MCM7</td>
<td>17</td>
</tr>
<tr>
<td>RPA1</td>
<td>16</td>
</tr>
<tr>
<td>RPA2</td>
<td>3</td>
</tr>
<tr>
<td>RPA3</td>
<td>1</td>
</tr>
<tr>
<td>PSF3</td>
<td>6</td>
</tr>
<tr>
<td>BOD1L</td>
<td>6</td>
</tr>
</tbody>
</table>

B

Input → IP → IB

CFlap-mBOD1L (αGFP) → MCM2

B

Input → IP → IB

CFlap-mBOD1L (αGFP) → MCM2

C

% Cell Survival

UV (J/m²)

Con siRNA

BOD1L siRNA

D

% of Cells

Number of micronuclei/cell

UV (J/m²)

Control siRNA

BOD1L siRNA

E

ScrF1 + ScrR1

ScrF2 + ScrR2

ScrF3 + ScrR3

ScrF4 + ScrR4

Control

F

GqBOD1L locus

BOD1L targeting vectors

Targeted locus

Scrf1

Scrf2

Scrf3

Scrf4

G

% Cell Survival

MMC (ng/ml)

WT cl.18

BOD1L cl.1

BOD1L cl.2

H

% of Cells

Number of micronuclei/cell

Number of micronuclei/cell

WT cl.18

BOD1L cl.1

BOD1L cl.2

Untreated

+ MMC
Figure S2

A) Average chromatid gaps/breaks per metaphase for untreated and MMC-treated cells in HeLa, A549, and U-2-OS cells.

B) Western blot analysis showing the expression of BOD1L and GFP in parental HeLa, HeLa CFip-mBod1L cl. 1-4, and HeLa CFip-mBod1L cl. 5-20 cells.

C) Percentage of cells with different number of micronuclei/cell after MMC treatment.

D) Chromatid gaps/breaks per metaphase for parental, parental + Con siRNA, C1-4 + Con siRNA, C5-20 + Con siRNA, parental + BOD1L siRNA, C1-4 + BOD1L siRNA, and C5-20 + BOD1L siRNA.

E) Immunofluorescence analysis showing FANCD2 localization with and without MMC treatment.

F) Time course of FANCD2 and mUb FANCD2 foci formation after MMC treatment in cells treated with Con siRNA and BOD1L siRNA.
Figure S4

A

RPA fluorescence intensity (AU)

Time (h) after HU

Con siRNA
BOD1L siRNA

B

γH2AX BrdU DAPI

Con siRNA + MMC
BRCA2 siRNA + MMC
BOD1L siRNA + MMC

C

% of all CldU labelled

Super-RPA

Con siRNA
BOD1L siRNA
Con siRNA + MMC
BOD1L siRNA + MMC

D

Fold change in chromatid gaps/breaks per metaphase

Super-RPA

Con siRNA
BOD1L siRNA

E

Super-RPA

Con siRNA
BOD1L siRNA
MMC

F

Parental

Control
BOD1L

RPA2-S4/8-P
RPA2
γ-H2AX
H2A

CFlap-BOD1L C1-4
CFlap-BOD1L C5-20

G

Time (h) after HU

RPA2 S4/8-P
RPA2
γ-H2AX
H2A

Control siRNA
BOD1L siRNA

LI WO
0 24 24 0 24 24
Figure S6

A

B

C

D

E

F

G

H

I

Figure S6
Figure S7

A

% of RPA/γH2A positive cells

+ MMC

Con siRNA
BOD1L siRNA
BLM siRNA
FBH1 siRNA
FBH1/BOD1L siRNA
RECQL5 siRNA
RECQL5/BOD1L siRNA

B

% of RAD51 positive cells

+ MMC

Con siRNA
BOD1L siRNA
BLM siRNA
BLM/BOD1L siRNA
FBH1 siRNA
FBH1/BOD1L siRNA
RECQL5 siRNA
RECQL5/BOD1L siRNA

C

diagram showing Western blots for BOD1L, RECQL5, and H2A

D

diagram showing Western blots for BOD1L, FBH1, RAD51, and H2A

E

diagram showing fluorescence images for RAD51 and DAPI

F

table showing average IdU:CldU ratio and SEM

<table>
<thead>
<tr>
<th>siRNA</th>
<th>Average IdU:CldU ratio</th>
<th>SEM</th>
<th>Average IdU:CldU ratio</th>
<th>SEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Con siRNA</td>
<td>1.02</td>
<td>0.01</td>
<td>1.00</td>
<td>0.01</td>
</tr>
<tr>
<td>BOD1L siRNA</td>
<td>1.02</td>
<td>0.02</td>
<td>0.69</td>
<td>0.02</td>
</tr>
<tr>
<td>FBH1 siRNA</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>BOD1L/FBH1 siRNA</td>
<td>0.99</td>
<td>0.02</td>
<td>0.90</td>
<td>0.03</td>
</tr>
<tr>
<td>BLM siRNA</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>BOD1L/BLM siRNA</td>
<td>0.97</td>
<td>0.01</td>
<td>0.88</td>
<td>0.01</td>
</tr>
<tr>
<td>RECQL5 siRNA</td>
<td>1.00</td>
<td>0.03</td>
<td>0.75</td>
<td>0.05</td>
</tr>
<tr>
<td>BOD1L/RECQL5 siRNA</td>
<td>0.99</td>
<td>0.01</td>
<td>0.59</td>
<td>0.01</td>
</tr>
</tbody>
</table>

G

% of cells with micronuclei

Micronuclei per cell

<table>
<thead>
<tr>
<th>siRNA</th>
<th>Input</th>
<th>αGFP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Con siRNA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BOD1L siRNA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BLM siRNA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BLM/BOD1L siRNA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FBH1 siRNA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FBH1/BOD1L siRNA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

H

diagram showing Western blots for RAD51

IB

Input

αGFP

CFlap-mBOD1L (αGFP)
SUPPLEMENTAL FIGURE LEGENDS

Figure S1: BOD1L ensures cellular viability and genome integrity after replication stress. Related to Figure 1. (A) Total peptides identified by mass spectroscopy analysis of EdU-coprecipitates isolated from HeLa S3 cells. A complete mass spectrometry data set is available on request to the Corresponding Author. (B) WCE from parental HeLa or HeLa-CFlap-mBod1L cells (clone 5-20; see also Figure S2B) were subjected to IP with anti-GFP antibody, and inputs and recovered immunoprecipitates were analyzed by immunoblotting. Blots originate from a single gel. A white line denotes removal of irrelevant lanes. (C) HeLa cells were transfected with the indicated siRNA for 72 h and exposed to the indicated doses of UV-C or aphidicolin (APH), left to form colonies for 14 days, and then stained with methylene blue and counted. (D) U-2-OS and H1299 cells were transfected as in (C), exposed to 50 ng/ml MMC for 24 h, and micronuclei formation was assessed by immunofluorescence. (E) PCR screening of WT and BOD1L-deleted (Δexon 1/Δexon 10) DT40 clones using the primers in (F). The presence of PCR products denotes successful recombination of the homology arms, and thus deletion of the desired region. (F) Schematic of the Gallus gallus BOD1L locus (upper) with targeting vectors spanning exons 1-5 and exon 10 (middle), and a schematic of the targeted Δexon 1/Δexon 10 locus (lower). Positions of screening primers are shown. (G) WT DT40s, and two clones lacking exons 1-5 and exon 10 of BOD1L, were exposed to the indicated doses of MMC, left to form colonies in soft agar, stained with methylene blue and counted. Plots represent mean data from four independent experiments; error bars represent SEM. Two-way ANOVA. (H) WT or BOD1L-deleted DT40s were exposed to 12.5 ng/ml MMC for 24 h, and micronuclei formation assessed by immunofluorescence. Plots represent mean data from three independent experiments; error bars represent SEM; Student’s t-test. * = p<0.05; *** = p<0.001.

Figure S2: BOD1L knockdown increases genomic instability after replication stress. Related to Figure 3. (A) HeLa, A549 and U-2-OS cells were treated as in Figure 3G, and damage to metaphase chromosomes was analysed by Geimsa staining and light microscopy.
Graphs integrate data from 50 cells for each condition from three independent experiments.

(B-D) Parental HeLa or HeLa-CFlap-mBod1L cells (clones C1-4 and C5-20) were transfected with the indicated siRNA for 72 h, and: (B) Whole cell extracts of cells (WCE) were analysed by immunoblotting; (C) Micronuclei formation was assessed by immunofluorescence; (D) Metaphase chromosomes were analysed by Geimsa staining and light microscopy. (E) HeLa cells from Figure 3A were immunostained with antibodies to FANCD2, and foci formation analysed by fluorescence microscopy. Plot indicates quantification of cells with more than 10 FANCD2 foci per cell from four independent experiments. (F) U-2-OS cells were transfected with the indicated siRNA for 72 h, exposed to 250 ng/ml MMC for 3 h, left to recover for the indicated times, and WCE were analysed by immunoblotting. Scale bars = 10 μm. NS = p>0.05; ** = p<0.01; Students’ t-test.

Figure S3: The effect of BOD1L depletion on DNA replication kinetics. Related to Figure 4. (A) Quantification of cell cycle profiles shown in Figure 4B. Data is representative of the mean ± SEM of four independent experiments. (B) Cells from (A) were immunostained with antibodies to phosphorylated histone H3-Ser10, and the percentage of mitotic cells determined by flow cytometry. Data represent mean ± SEM of four independent experiments. (C) DNA fibres from Figure 4E were quantified. The percentages of ongoing forks, first-label (bidirectional) origins, new origins (IdU-labelled only), first-label terminations (CldU-labelled only) and second label terminations are displayed. (D) HeLa cells were treated as in Figure 4E except that, where indicated, they were treated with CDK1/2 inhibitor for 3 h prior to pulse labelling. Plot displays percentage of new origins (IdU-labelled only). (E) U-2-OS cells were transfected with the indicated siRNA for 72 h, and DNA fibres prepared as in Figure 4E. The percentage of new origins (IdU-labelled only) is displayed. (F) HeLa cells were transfected with the indicated siRNAs, and the DNA combed and analysed as above. (G) Cells were treated as in Figure 4D, except that, where indicated, they were treated with CDK1/2 inhibitor for the duration of HU exposure (2 h). Plots display average percentages of the relevant fork
structure(s) from three independent experiments; error bars represent SEM. ** = p<0.01; Students’ t-test.

**Figure S4: BOD1L is necessary to prevent excessive ssDNA formation and RPA2 hyper-phosphorylation after replication stress. Related to Figure 5.** (A) Foci formation in HeLa cells from Figure 5B was analysed by fluorescence microscopy, and fluorescence intensity per nucleus was quantified using ImageJ. Lines denote mean values from three independent experiments. (B) U-2-OS cells were treated as in Figure 5C, and immunostained with antibodies to BrdU and γH2AX. Representative images are shown. Scale bars = 10 μm. (C-E) Vector U-2-OS or SUPER-RPA U-2-OS cells were transfected with the indicated siRNAs and exposed to 50 ng/ml MMC for 24 h. (C) Left panel: WCE of the indicated cell lines were analysed by immunoblotting. Right panel: Transfected Vector or SUPER-RPA cells were treated as in Figure 4E, and the plots display the percentage of new origins (IdU-labelled only). (D) Damage to metaphase chromosomes was analysed by Geimsa staining and light microscopy. Graphs integrate data from 150 cells, in total, for each condition from three independent experiments, and are displayed as fold change compared to control siRNA-transfected cells. (E) WCE of the indicated cell lines were analysed by immunoblotting. (F) Parental HeLa or HeLa-CFlap-mBod1L cells (clones C1-4 and C5-20) were transfected with the indicated siRNA for 72 h, exposed to 50 ng/ml MMC for 24 or 48 h, and WCE were analysed by immunoblotting. (G) HeLa cells were transfected with the indicated siRNA for 72 h, exposed to 250 μM HU for 24 h, and harvested immediately (LI), or left to recover for a further 24 h (WO). WCE were analysed by immunoblotting.

**Figure S5: BOD1L is required to suppress aberrant end resection at replication forks after replication stress. Related to Figure 6.** (A) U-2-OS cells were transfected with the indicated siRNAs for 72 h, pulsed for 20 min each with CldU and IdU, and exposed to 4 mM HU for 5 h. DNA was visualised with antibodies to CldU and IdU, and replication fork length was calculated. Plots denote the average ratios of IdU:CldU label lengths from three
independent experiments. Arrows indicate mean ratios. (Inset) WCE of cells were analysed by immunoblotting. Control siRNA panel is from the same gel as in Figure S7C. A white line denotes removal of irrelevant lanes. (B) Average values of IdU:CldU label lengths from DNA isolated from cells in Figures 6A and S6A is indicated, and SEM are denoted. (C) HeLa cells were transfected for 72 h with the indicated siRNAs, exposed to the indicated doses of MMC, left to form colonies for 14 days, and then stained with methylene blue and counted. Plots denote the average values from three independent experiments. (D) WCE of cells from (C) were analysed by immunoblotting. Loading control denotes a non-specific protein detected by anti-BOD1L antibody. (E) HeLa cells from (C) were exposed to 50 ng/ml MMC for 24 h, immunostained with antibodies to RPA2 and phospho-RPA S4/S8, and foci formation was analysed by fluorescence microscopy. The average percentage of double-positive cells is shown. (F) HeLa cells were transfected with the indicated siRNA for 72 h, exposed to 50 ng/ml MMC for 24 h, immunostained with antibodies to RPA2 and phospho-RPA S4/S8, and foci formation was analysed by fluorescence microscopy. The average percentage of double-positive cells from three independent experiments is shown. (G) WCE of HeLa cells from (F) were analysed by immunoblotting. (H) DNA from U-2-OS cells in Figure 6C was visualised with antibodies to CldU and IdU, and replication fork length was calculated. Average values and SEM are denoted. (I-J) HeLa cells were transfected with the indicated siRNAs, exposed to 50 ng/ml MMC for 24 h, and either: RAD51 foci formation was analysed by fluorescence microscopy (I); or RAD51 expression was analysed by immunoblotting (J). siRNAs 18-21 were individual siRNAs from the SMARTpool.

**Figure S6: BOD1L enables RAD51 chromatin loading to promote efficient homologous recombination. Related to Figure 6.** (A) HeLa cells were transfected with the indicated siRNA for 72 h, exposed to 50 ng/ml MMC for 24 h, and immunostained with antibodies to RAD51. Foci formation was analysed by fluorescence microscopy, and quantified into three distinct phenotypes (representative images are shown in the lower panel). (B-C) Parental HeLa or HeLa-CFlap-mBod1L cells (clones C1-4 and C5-20) were transfected with the
indicated siRNA for 72 h, exposed to 50 ng/ml MMC, and immunostained with antibodies to RAD51. (B) Foci formation was analysed by fluorescence microscopy and quantified. (C) Representative images are shown. (D) The incidence of radial chromosome formation was analysed from metaphase spreads prepared as described in Figure 3G. ** = p<0.01; Students’ t-test. (E) HeLa cells were transfected with the indicated siRNA for 24 h, labelled with BrdU for a further 24 h, and exposed to 25 ng/ml MMC for a further 24 h. Sister chromatid exchanges were quantified from at least 50 cells from three independent metaphase spreads. Line = mean number of SCEs/chromosome. Error bars = SEM. *** = p<0.001; Mann-Whitney ranked sum test. (F) HeLa cells were transfected with the indicated siRNA for 72 h, exposed to 5 Gy of γ-irradiation, and immunostained with antibodies to RAD51. Scale bars = 10 μm. (G-I) The prevalence of nuclear foci of BRCA1, BRCA2, and PALB2-GFP in HeLa or U-2-OS-PALB2-GFP cells from Figure 6H. Foci formation was analysed by fluorescence microscopy, and representative images are shown.

Figure S7: BOD1L acts to restrain anti-recombinase activity to stabilise RAD51 chromatin loading and prevent excessive resection of replication forks. Related to Figure 7. (A-B) HeLa cells were treated as in Figure 7A/B, and RPA2/RPA2-PS4/8 foci formation (A) or RAD51 foci formation (B) was analysed by fluorescence microscopy. The average percentage of double-positive cells (A) or RAD51-positive cells (B) is shown. (C) WCE of cells from (A) were analysed by immunoblotting. (D) U-2-OS cells were transfected with the indicated siRNAs, exposed to 100 ng/ml MMC for 24 h, and then fractionated. Soluble and chromatin fractions were analysed by immunoblotting. Blots originate from a single gel. A white line denotes removal of irrelevant lanes. (E) HeLa cells were transfected with the indicated siRNA for 72 h, exposed to 50 ng/ml MMC for 24h, and immunostained with antibodies to RAD51. Scale bars = 10 μm. (F) U-2-OS cells were treated as in Figure 7C, and IdU:CldU ratios were calculated in the presence/absence of HU. Average values and SEM are denoted. (G) Micronuclei formation was assessed by immunofluorescence in HeLa cells from Figure 7A. (H) WCE from parental HeLa or HeLa-CFlap-mBod1L cells from Figure S1B were
subjected to IP with anti-GFP antibody, and inputs and recovered immunoprecipitates were analyzed by immunoblotting. The upper panel is identical to that shown in Figure S1B. A white line denotes removal of irrelevant lanes.
SUPPLEMENTAL EXPERIMENTAL PROCEDURES

Cell lines
A549, HeLa, HeLa S3, U-2-OS, and H1299 were sourced from the ATCC. U2OS-PALB2-GFP were obtained from F. Esashi. HeLa-FUCCI were obtained from RIKEN BRC.

Drugs and inhibitors
HU, Aphidicolin, and MMC were from Sigma Aldrich, and were used as indicated in the Figure Legends. Cdk1/2 inhibitor III was used at 25 μM (Merck). dNTP analogues BrdU, EdU, CldU and IdU were from Sigma Aldrich, and were used as indicated. Mirin (Calbiochem) was used at 50 μM.

Generation of HeLa-CFlap-BOD1L cells.
A BAC containing the full length Mus musculus BOD1L locus was obtained from BacPac Resources. This BAC was modified to insert a C-terminal Flap tag by Red/ET recombination following a modified protocol from Genebridges. To generate HeLa-CFlap-BOD1L cells, HeLa cells have been transfected with CFlap-Bod1L BAC using Lipofectamine 2000 (Invitrogen), then selected for 3 weeks with Geneticin and single cell-sorted by FACS following high level of GFP expression. Two clones (C1-4 and C5-20) were expanded and used for further experiments.

Generation of BOD1L knock out DT40 cell lines.
BOD1L knock out DT40 cell lines were generated using two disruption cassettes targeting exons 1-5 and targeting exon 10 of the chicken BOD1L locus. The chicken BOD1L locus was identified by BLAST search using the human protein sequence against the ENSEMBL draft chicken genome sequence. An ENSEMBL predicted transcript encompassed the entire BOD1L gene. From this sequence, two disruption cassettes targeting exons 1-5 and targeting exon 10 were designed. PCR oligos used to amplify 5’ and 3’ arms of the first construct targeting exons 1-5 were
PCR oligos used to amplify 5’ and 3’ arms of the second construct targeting exon 10 were

AATATAAGCTTGCAGCCGGCGCGTTGTCAAAAGGACATCTG

GTCAAGCTTCTATTTGGCATCTGTGCTTTGACTG

and

GTACTTGAGTACGTGTAATCAGTGCAAGTGCTGATG

GGCAAAGCTTATAGCGAGGGTTGAACAGATG

respectively. Targeting constructs were generated by cloning the PCR products into the pSH vector containing either puromycin or hygromycin resistance. Transfections and selection of targeted DT40 clones were carried out as described previously (Niedzwiedz et al., 2004). To confirm the appropriate disruptions of the GgBOD1L locus, genomic DNA was obtained and the following PCR oligos were used to screen the clones: ScrF1, TGCATCAGGGATGACATTCTC; ScrR1, TAAGACTGCTGCTGACACCTTCAC; ScrF2, GCGGGACTATGGTTGCTGACTAATTGAG; ScrR2, ACTAGCTGCGTCCCAAAGAGTTTC; ScrF3, GCTGGCATGCTGGAATGTACTTTATGG; ScrR3, CTTCACAGGCGAGTACTTCTGTAAC; ScrF4, ACGATTCGAGCCCACCTTCTTAG; ScrR4, ATCTTTGGAGATGTCTTAAGGCCAGGTC (Figure S1E).

siRNA Transfections

siRNAs were from Dharmacon as SMARTpool (SP) or individual siRNAs deconvolved from the SMARTpool: BOD1L (SP, siRNA-18, -19, -20, -21); BOD1 (SP). SP and BOD1L siRNA-19 were used for all experiments unless stated. siRNA transfections were performed with siRNA duplexes (100 nM) using Oligofectamine (Invitrogen). Whenever siRNAs were combined, the total concentration was kept at 100 nM. A custom siRNA targeting lacZ (CGUACGCGGAUACUGAdTdT) was used as a scrambled, non-targeting siRNA, and is
abbreviated as “Control siRNA”, or “Con siRNA”. All experiments were performed 72 h post knockdown unless otherwise stated.

**Colony survival assays**

Colony survival assays using HeLa cells were carried out as described (Stewart *et al.*, 2003). For colony survival assays with DT40 cells, MMC-treated cells were plated in methylcellulose after exposure to a range of concentrations of the drug. Viable colonies were scored after 2-3 weeks.

**DNA combing**

DNA combing was carried out essentially as described previously (Petermann *et al.*, 2010). HU (2 mM) or MMC (50 ng/ml) treatments were for 2 h or 24 h respectively. For resection experiments, cells were pulse-labelled with CldU and IdU for 20 min each before a 5 h exposure to 4 mM HU. For quantification of replication structures, at least 250 structures were counted per experiment. The lengths of red or green labelled tracts were measured using ImageJ (National Institutes of Health; http://rsbweb.nih.gov/ij/) and arbitrary length values were converted into micrometers using the scale bars created by the microscope.

**Chromatin fractionation**

Subcellular fractionations were performed in U-2-OS cells essentially as described in (Mendez and Stillman, 2000), except that chromatin fractions were washed once after isolation in 200 mM NaCl, 3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, plus protease inhibitor cocktail, and resuspended in UTB.

**Metaphase spreads, SCEs and FISH**

Chromosomal aberrations and sister chromatid exchanges (SCEs) were scored in Giemsa stained metaphase spreads. For chromosome aberrations, demecolcine (Sigma) was added 3-4 h prior to harvesting at a final concentration of 0.2 µg/ml. Cells were harvested by
trypsinisation, subjected to hypotonic shock for 1 hour at 37°C in 0.3 M sodium citrate and
fixed in 3:1 methanol:acetic acid solution. Cells were dropped onto acetic acid humidified
slides, stained for 15 minutes in Giemsa-modified (Sigma) solution (5% v/v in H2O) and
washed in water for 5 minutes.

For SCEs, 10 µM BrdU (Sigma) was added to the medium for two complete cycles
(approximately 48 hours) before collection and 25ng/ml MMC was added 24 h before
collection. 0.2 µg/ml demecolcine was added 3 h prior to harvesting and metaphase spreads
were obtained as described above. Before Giemsa staining, slides were incubated in Hoescht
33258 solution (10 µg/ml) for 20 minutes, exposed to UV light (355 nm) for 1 hour and washed
for 1 hour at 60°C in 20× SCC. Cells were harvested as described above.

Fragile site FISH was performed as previously described by (Le Tallec et al., 2011). Probes
for the common fragile sites FRA3B and FRA16D were made from BACs RP11-170K19 and
RP11-281J9, respectively (Children’s Hospital Oakland Research Institute) and were labelled
with Biotin-conjugated nucleotides using the BIOPRIME DNA Labelling System (Invitrogen)
according to manufacturer’s protocol. For dioxigenin incorporation, the BIOPRIME DNA
Labelling System was used, but Dioxigenin-conjugated dNTPs (Roche) were used instead of
biotin-conjugated dNTPs. Probes were purified using Illustra Probequant G-50 micro columns
(GE Healthcare).

Flow cytometry
Flow cytometry was carried out as described previously (Townsend et al., 2009). Briefly, HeLa
cells were harvested, fixed in 70% ethanol at -20°C for at least 1 h, and permeabilised with
0.25% Triton-X100 for 15 at 4°C. For immuno-detection of phospho-histone H3 (Ser10), cells
were then incubated with primary antibody for 1 h, washed in 1% BSA, and counterstained
with Alexa Fluor-488 goat anti-mouse IgG antibody. Cells were then washed twice with 1%
BSA, and stained with 25 µg/ml propidium iodide containing 0.1 mg/ml RNase A. Cells were
analysed using an Accuri flow cytometer (BDBiosciences) in conjunction with CFlowplus software. Data represents that obtained from at least 30,000 cells.

**Antibodies and Western blotting**

Whole cell extracts were obtained by sonication in UTB buffer (8 M Urea, 50 mM Tris, 150 mM β-mercaptoethanol, protease inhibitor cocktail (Roche)) and analysed by SDS-PAGE following standard procedures. The following antibodies were used: H2A, γ-H2AX, BRCA2, RPA2, RAD51 (Merck Millipore); MRE11, phospho-histone H3 Ser-10, phospho-CDK2 Tyr-15 (Cell Signalling); MCM7, CHK1, PCNA, CDK2, FANCD2, BRCA1, BRCA2 (Santa Cruz Biotechnology); RECQL5, FANCA, EXO1, phospho-RPA2 Ser-4/8, phospho-CHK1 Ser-317, phospho-CHK1 Ser-345, MLL1 (Bethyl); CENPA, DNA2, BOD1, PCNT-1 (Abcam), α-tubulin, FLAG (Sigma Aldrich); GFP (Roche); BrdU (CldU) (AbD Serotec); BrdU (IdU) (Becton Dickinson); MCM2 (BD Transduction); 53BP1 (G. S. Stewart); PICH (H. Yu). Affinity purified polyclonal anti-BOD1L antibodies were generated by immunising rabbits with a purified GST-fusion protein spanning amino acids 1,900 to 2,501 of human BOD1L (Accession number: NP_683692.2) (Eurogentec).

**Immunoprecipitations**

HeLa nuclear cells extracts (Cilbiotech) were clarified by centrifugation at 44,000 x g, immunoprecipitated with 5 μg of anti-BOD1L antibody or IgG for 3 h at 4 °C. After further clarification, immune complexes were isolated using protein-A sepharose (GE Healthcare), and analysed by immunoblotting.

**iPOND**

*EdU-labeled sample preparation:* Logarithmically growing HeLa S3 cells (1 x 10^6 per ml) were incubated with 10 mM EdU for 10 min. Following EdU labelling, cells were fixed in 1 % formaldehyde, quenched by adding glycine to a final concentration of 0.125 M and washed in PBS three times. Collected cell pellets were frozen at -80 °C and cells were permeabilised by
resuspending in ice cold 0.25 % Triton-X/PBS at a concentration of 1-1.5 x 10^7 cells per ml and incubating on ice for 30 min. Before the Click reaction, samples were washed once in 0.5 % BSA/PBS and once in PBS.

**Click reaction:** Cells were incubated in Click reaction buffer for 1h at room temperature containing 10 µM azide-PEG(3+3)-S-S-biotin conjugate (Click ChemistryTools, cat. no AZ112-25), 10 mM sodium ascorbate, and 1 mM copper (II) sulfate (CuSO4) in PBS. The ‘no Click’ reaction contained DMSO instead of biotin-azide. Following the Click reaction, cells were washed once in 0.5 % BSA/PBS and once in PBS. Cells were resuspended in lysis buffer (50 mM Tris–HCl pH 8.0, 1 % SDS) containing protease inhibitor cocktail (Roche) and sonicated using a Diagenode Bioruptor® Plus for 40 cycles (30 sec on/30 sec off). Samples were centrifuged at 14,500 xg at 4°C for 30 min and the supernatant was diluted 1:3 with NTN buffer (100 mM NaCl, 20 mM Tris pH 7.4 and 0.05 % NP40) containing protease inhibitors. An aliquot was taken as an input sample.

**Purification:** Streptavidin–agarose beads (Novagen) were washed three times in NTN buffer containing protease inhibitor cocktail. 200 µl of bead slurry was used per 1x 10^8 cells. The streptavidin–agarose beads were resuspended 1:1 in NTN buffer containing protease inhibitors and added to the samples. Samples were then incubated at 4 °C for 4 h in light exclusion. Following binding, the beads were then washed 4x with 1 ml NTN buffer and protein-DNA complexes were eluted by incubating with 5mM DTT in NTN buffer. Cross-links were reversed by incubated samples in SDS sample buffer at 95 °C for 12 min. Proteins were resolved on SDS-PAGE and detected by immunoblotting, or mass-spectrometry analysis was performed on the eluates. Mass spectrometry was carried out as described previously (Adelman et al., 2013). A complete mass spectrometry data set is available on request to the Corresponding Author.
Microscopy and Image Analysis

HeLa, H1299, U-2-OS, HeLa-FUCCI or A549 cells were grown on glass coverslips. DT40 cells were grown in suspension, and dropped onto poly-L-lysine coated coverslip for 15 min. Cells were washed with PBS twice before fixation. For α-tubulin, PCNT-1, PCNA, CENPA and 53BP1 immuno-detection, cells were fixed with methanol at -20 °C for 10 minutes. For PICH, FANCD2 and EdU detection, and for 53BP1 immuno-detection in FUCCI cells, cells were fixed in 3.6% paraformaldehyde for 10 min at room temperature before permeabilisation with nuclear extraction buffer (10 mM PIPES, 20 mM NaCl, 3 mM MgCl₂, 300 mM sucrose, 0.5% Triton X-100) for 10 minutes. For RAD51, γ-H2AX, BRCA2 and RPA immuno-detection, cells were pre-treated with nuclear extraction buffer for 5 minutes on ice, and fixed in 3.6% paraformaldehyde for 10 minutes at room temperature. For in situ detection of nascent DNA in mitotic and interphase cells the Click-iT DNA Alexa Fluor 495 Imaging Kit (Invitrogen) was used. For ssDNA (BrdU) analyses, cells were pre-treated with nuclear extraction buffer for two 5 consecutive minute incubations on ice, then fixed as above. After fixation, cells were washed with PBS three times and then blocked with ADB (Antibody Dilution Buffer; 5% FCS in PBS) for 1 h at 4°C. Cells were incubated with primary antibody (diluted in ADB) for 1 h at room temperature, washed with ADB and then counterstained with Alexa Fluor-488 goat anti-rabbit IgG, Alexa Fluor-594 goat anti-mouse IgG, Alexa Fluor-350 goat anti-rabbit IgG, or Alexa Fluor-555 donkey anti-rabbit IgG secondary antibodies (Molecular Probes) diluted in ADB, for 1 h at room temperature. Cells were then washed twice with ADB and coverslips were mounted onto glass slides with Vectashield mounting agent containing 0.4 μg/ml DAPI (Vectashield). Fluorescence images were taken using a Nikon E600 Eclipse microscope equipped with a 60X oil lens, and images were acquired and analysed using Volocity Software v4.1 (Improvision). For ssDNA analyses, BrdU foci were enhanced using the ImageJ convolve function, and the number of nuclear foci/cell quantified.

Proximity ligation assays
For proximity ligation assays (PLA), cells were fixed/permeabilised as appropriate for the primary antibodies used, incubated in primary antibody, and in situ proximity ligation was performed using Duolink Detection Kit in combination with anti-Mouse PLUS and anti-Rabbit MINUS PLA Probes, according to the manufacturer’s instructions (Sigma Aldrich Duolink). Nuclear foci were imaged as above, and the number of nuclear foci/cell quantified using ImageJ.
SUPPLEMENTAL REFERENCES


